Cost effectiveness of immune checkpoint inhibitors for treatment of non-small cell lung cancer: A systematic review

被引:38
作者
Ding, Haiying [1 ,2 ]
Xin, Wenxiu [1 ]
Tong, Yinghui [1 ]
Sun, Jiao [1 ]
Xu, Gaoqi [1 ]
Ye, Ziqi [2 ]
Rao, Yuefeng [2 ]
机构
[1] Chinese Acad Sci, Dept Pharm, Inst Canc & Basic Med IBMC, Univ Chinese Acad Sci,Zhejiang Canc Hosp,Canc Hos, Hangzhou, Peoples R China
[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Pharm, Hangzhou, Peoples R China
来源
PLOS ONE | 2020年 / 15卷 / 09期
关键词
OF-CARE CHEMOTHERAPY; ECONOMIC-EVALUATION; 1ST-LINE TREATMENT; OPEN-LABEL; PEMBROLIZUMAB; PD-L1; DOCETAXEL; NIVOLUMAB; NSCLC; THERAPIES;
D O I
10.1371/journal.pone.0238536
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background Immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC) have been rapidly evolving. ICIs are likely to be more effective but also lead to escalating healthcare costs. Objectives The aim of this study was to evaluate the cost effectiveness of immune checkpoint inhibitors (ICIs) for treatment of non-small cell lung cancer (NSCLC). Methods We searched the PubMed, Web of Science, and Cochrane Library for studies comparing the cost effectiveness of ICIs for NSCLC. Potential studies identified were independently checked for eligibility by two authors, with disagreement resolved by a third reviewer. Quality of the included studies was evaluated using Consolidated Health Economic Evaluation Reporting Standards checklists. Results A total of 22 economic studies were included. Overall reporting of the identified studies largely met CHEERS recommendations. In the first-line setting, for advanced or metastatic NSCLC patients with PD-L1 >= 50%, pembrolizumab appeared cost-effective compared with platinum-based chemotherapy in the US and Hong Kong (China), but not in the UK and China. The cost-effectiveness of pembrolizumab versus chemotherapy for first-line treatment of NSCLC in PD-L1 >= 1% patients remained obscure. Regardless of PD-L1 expression status, pembrolizumab in combination with chemotherapy could be a cost-effective first-line therapy in the US. On the contrary, addition of atezolizumab to the combination of bevacizumab and chemotherapy was not cost-effective for patients with metastatic non-squamous NSCLC from the US payer perspective. In the second-line setting compared with docetaxel, pembrolizumab was cost-effective; though nivolumab was not cost-effective in the base case, it could be by increased PD-L1 threshold. Results of the cost-effectiveness of atezolizumab second-line treatment remained inconsistent. In addition, the adoption of durvalumab consolidation therapy after chemoradiotherapy could be cost-effective versus no consolidation therapy for patients with stage III NSCLC. Conclusions Immunotherapy can be a cost-effective option for treatment of NSCLC in several scenarios. A discount of the agents or the use of PD-L1 expression as a biomarker improves the cost-effectiveness of immunotherapy.
引用
收藏
页数:16
相关论文
共 48 条
[11]   Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].
Gandhi, L. ;
Rodriguez-Abreu, D. ;
Gadgeel, S. ;
Esteban, E. ;
Felip, E. ;
De Angelis, F. ;
Domine, M. ;
Clingan, P. ;
Hochmair, M. J. ;
Powell, S. F. ;
Cheng, S. Y. -S. ;
Bischoff, H. G. ;
Peled, N. ;
Grossi, F. ;
Jennens, R. R. ;
Reck, M. ;
Hui, R. ;
Garon, E. B. ;
Boyer, M. ;
Rubio-Viqueira, B. ;
Novello, S. ;
Kurata, T. ;
Gray, J. E. ;
Vida, J. ;
Wei, Z. ;
Yang, J. ;
Raftopoulos, H. ;
Pietanza, M. C. ;
Garassino, M. C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092
[12]   Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models [J].
Gao, Lan ;
Li, Shu-Chuen .
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2019, 17 (03) :371-380
[13]   Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer [J].
Georgieva, Mina ;
da Silveira Nogueira Lima, Joao P. ;
Aguiar, Pedro ;
Lopes, Gilberto de Lima, Jr. ;
Haaland, Benjamin .
LUNG CANCER, 2018, 124 :248-254
[14]   Economic evaluation of nivolumab for the treatment of second-line advanced squamous NSCLC in Canada: a comparison of modeling approaches to estimate and extrapolate survival outcomes [J].
Goeree, Ron ;
Villeneuve, Julie ;
Goeree, Jeff ;
Penrod, John R. ;
Orsini, Lucinda ;
Monfared, Amir Abbas Tahami .
JOURNAL OF MEDICAL ECONOMICS, 2016, 19 (06) :630-644
[15]   Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer [J].
Hellmann, M. D. ;
Paz-Ares, L. ;
Bernabe Caro, R. ;
Zurawski, B. ;
Kim, S. -W. ;
Carcereny Costa, E. ;
Park, K. ;
Alexandru, A. ;
Lupinacci, L. ;
de la Mora Jimenez, E. ;
Sakai, H. ;
Albert, I. ;
Vergnenegre, A. ;
Peters, S. ;
Syrigos, K. ;
Barlesi, F. ;
Reck, M. ;
Borghaei, H. ;
Brahmer, J. R. ;
O'Byrne, K. J. ;
Geese, W. J. ;
Bhagavatheeswaran, P. ;
Rabindran, S. K. ;
Kasinathan, R. S. ;
Nathan, F. E. ;
Ramalingam, S. S. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :2020-2031
[16]   Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057) [J].
Horn, Leora ;
Spigel, David R. ;
Vokes, Everett E. ;
Holgado, Esther ;
Ready, Neal ;
Steins, Martin ;
Poddubskaya, Elena ;
Borghaei, Hossein ;
Felip, Enriqueta ;
Paz-Ares, Luis ;
Pluzanski, Adam ;
Reckamp, Karen L. ;
Burgio, Marco A. ;
Kohlhaeeufl, Martin ;
Waterhouse, David ;
Barlesi, Fabrice ;
Antonia, Scott ;
Arrieta, Oscar ;
Fayette, Jerome ;
Crino, Lucio ;
Rizvi, Naiyer ;
Reck, Martin ;
Hellmann, Matthew D. ;
Geese, William J. ;
Li, Ang ;
Blackwood-Chirchir, Anne ;
Healey, Diane ;
Brahmer, Julie ;
Eberhardt, Wilfried E. E. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (35) :3924-+
[17]   First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective [J].
Hu, Xiaohan ;
Hay, Joel W. .
LUNG CANCER, 2018, 123 :166-171
[18]   Cost-effectiveness of pembrolizumab versus chemotherapy as first-line treatment in PD-L1-positive advanced non-small-cell lung cancer in the USA [J].
Huang, Min ;
Lopes, Gilberto de Lima ;
Insinga, Ralph P. ;
Burke, Thomas ;
Ejzykowicz, Flavia ;
Zhang, Ying ;
Feliciano, Josephine L. .
IMMUNOTHERAPY, 2019, 11 (17) :1463-1478
[19]   Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States [J].
Huang, Min ;
Lou, Yanyan ;
Pellissier, James ;
Burke, Thomas ;
Liu, Frank Xiaoqing ;
Xu, Ruifeng ;
Velcheti, Vamsidhar .
PHARMACOECONOMICS, 2017, 35 (08) :831-844
[20]   Cost-effectiveness of pembrolizumab versus docetaxel for the treatment of previously treated PD-L1 positive advanced NSCLC patients in the United States [J].
Huang, Min ;
Lou, Yanyan ;
Pellissier, James ;
Burke, Thomas ;
Liu, Frank Xiaoqing ;
Xu, Ruifeng ;
Velcheti, Vamsidhar .
JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (02) :140-150